AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice
- PMID: 42550908
- PMCID: PMC13462369
- DOI: 10.1073/pnas.2614476123
AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, produce robust and sustained weight loss, yet the central mechanisms supporting their long-term efficacy remain incompletely understood. Agouti-related peptide (AgRP) neurons of the arcuate nucleus are classically activated by negative energy balance and promote feeding and energy conservation. Based on this framework, GLP-1RAs have generally been expected to suppress or bypass AgRP neuron activity. Here, we report that AgRP neuron activation is required for the full weight-lowering effects of GLP-1RAs in female mice. Across complementary AgRP loss-of-function models, disruption of AgRP circuit integrity reduced the full weight-lowering effects of GLP-1RAs. This requirement varies with sex, diet, and mode of AgRP disruption. We found that GLP-1RA treatment is associated with increased markers of neuronal activation, mitochondrial engagement, and synaptic remodeling in AgRP neurons. We further identify a glucocorticoid-to-AgRP signaling axis as an important pathway mediating this functional recruitment of AgRP neurons. Together, these findings reveal that contrary to prevailing assumptions, GLP-1RA engages AgRP neurons to sustain weight loss, highlighting an unexpected role for these neurons in coordinating adaptive metabolic responses to pharmacologically induced negative energy balance.
Keywords: AgRP; diet; hypothalamus; metabolism; semaglutide.
Conflict of interest statement
Competing interests statement:The authors declare no competing interest.
References
-
- Wilding J. P. H., et al. , Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 (2021). - PubMed
-
- Wharton S., et al. , Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity 31, 703–715 (2023). - PubMed
-
- D’Ávila M., Hall S., Horvath T. L., GLP-1, GIP, and glucagon agonists for obesity treatment: A hunger perspective. Endocrinology 165, bqae128 (2024). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
